Transcranial Magnetic Stimulation is an FDA-Approved (2008) treatment for patients suffering from treatment resistant major depression, offering an alternative to treatment resistant medication. TMS is covered by most insurance providers, including Medicare. The TMS protocol offered at Spark TMS is established for the patient under the direct supervision of Andrew Peshek, M.D. Dr. Peshek has over 15 years of experience in the field of psychiatry. He obtained his medical degree from Case Western Reserve University School of Medicine in Cleveland, Ohio, and then completed his residency and fellowship at The University of Pennsylvania. His experience has been varied. He has taught psychopharmacology to students and medical staff at the Philadelphia VAMC. Dr. Peshek was Medical Director at Philadelphia Consultation Center for over 10 years, and is now in private practice with offices in Old City and South Philadelphia.
Dr. Peshek’s background and experience in TMS dates back to June of 2004. After completing his Psychiatry Residency at The University of Pennsylvania, he accepted a fellowship position in Mood & Anxiety Disorders at U Penn, where he worked on clinical trials in Neuromodulation, including the FDA-pivotal trial for TMS. In April of 2016, given his focus on treating patients with mood and anxiety disorders, as well as his background in neuromodulation, Dr. Peshek determined to incorporate TMS therapy into his practice.
Due to the growing demand for TMS therapy and the need to make this treatment available to patients outside of his own practice, Spark TMS was opened in October of 2018. Dr. Peshek serves as medical director establishing the necessary TMS protocols for each patient. Spark currently uses a new state of the art MagStim Horizon TMS Therapy system. TMS therapy is not intended as a substitute for therapeutic counseling, but is rather an adjunct therapy in lieu of or in addition to medication.